Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT00151320 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

Start date: January 2004
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objective: To determine the toxicity profile and maximum tolerated dose (MTD) of VELCADE when administered in combination with CHOP + Rituximab to patients with previously untreated diffuse large B cell or mantle cell non-Hodgkin's lymphoma (NHL) Secondary Objectives: To assess the response rate (overall and complete), event-free survival and overall survival with VELCADE and CHOP-R in patients with previously untreated diffuse large B cell or mantle cell lymphoma (phase II component) Treatment: Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications) VELCADE is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule: Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4

NCT ID: NCT00151281 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

Start date: November 2004
Phase: Phase 2
Study type: Interventional

Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be assessed. Secondary Objectives: 1. Assess the toxicity profiles of RT-PEPC treatment in patients with relapsed mantle cell lymphoma. 2. Prospectively characterize the angiogenic profile of patients with mantle cell lymphoma during treatment with RT-PEPC. The dynamics of the angiogenic profile will be correlated with clinical response to RT-PEPC therapy. 3. Assess the quality of life of patients receiving RT-PEPC treatment

NCT ID: NCT00147953 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma

Start date: June 2004
Phase: Phase 2
Study type: Interventional

This study aims to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkin's lymphoma.

NCT ID: NCT00147121 Completed - Lymphoma, B-Cell Clinical Trials

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Start date: September 2002
Phase: Phase 2/Phase 3
Study type: Interventional

To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma

NCT ID: NCT00146055 Completed - Clinical trials for Myelodysplastic Syndromes

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Start date: March 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether a less-intensive preparative therapy followed by an allogeneic peripheral stem cell transplantation will provide an effective treatment for your disease and whether it will be associated with fewer side effects.

NCT ID: NCT00145600 Completed - Hodgkin Lymphoma Clinical Trials

Therapy for Pediatric Hodgkin Lymphoma

Start date: March 2, 2000
Phase: Phase 2
Study type: Interventional

With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls.

NCT ID: NCT00145002 Completed - Lymphoma Clinical Trials

A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)

Start date: August 1998
Phase: Phase 3
Study type: Interventional

To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.

NCT ID: NCT00144807 Completed - Clinical trials for Diffuse Large Cell Lymphoma

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma

NCT ID: NCT00144755 Completed - Clinical trials for Diffuse Large Cell Lymphoma

R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma

Start date: December 2003
Phase: Phase 3
Study type: Interventional

This study is a multicentric randomized trial evaluating the efficacy and safety of R-CHOP given every 14 days compared to R-CHOP given every 21 days in association or not with darbepoetin alfa in order to maintain hemoglobin above 13 g/dl, compared to classical symptomatic treatment of anemia in patients aged from 60 to 80 years with diffuse large B-cell lymphoma.

NCT ID: NCT00144092 Completed - Low Grade Lymphoma Clinical Trials

HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma

Start date: May 2001
Phase: Phase 2
Study type: Interventional

Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation.